Ongericimab

昂戈瑞西单抗

Report date: 2025/06/09 14:19:26

Base Information

Drug NameOngericimab
Drug Alias Name君适达JS-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[8] 
Global Approved IndicationsHypercholesterolemiaDyslipidemias
Approved Indications in ChinaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryMainland China
Original Approved Date2024/10/09
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Junshi Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Bochuang Pharmaceutical Co LtdSuzhou Union Biopharm Biosciences Co LtdShanghai Junshi Biosciences Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[5] 
Inactive IndicationsHypertriglyceridemiaAtherosclerosisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A